🔎 Trials Near Me

Beranda › Kardiomiopati › Pennsylvania

Uji klinis Kardiomiopati di Pennsylvania

6 studi untuk Kardiomiopati mencari peserta di lokasi di Pennsylvania.

Kota di Pennsylvania

Teks studi resmi (Bahasa Inggris)

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  • Clinical Trial Site, Lancaster
  • Clinical Trial Site, Philadelphia
Menerima pesertaFase 3
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT07052903

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

  • Clinical Trial Site, Philadelphia
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07358078

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  • Penn Presbyterian Medical Center, Philadelphia
  • University of Pittsburgh Medical Center, Presbyterian Hospital, Pittsburgh
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06563895

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

  • University of Pennsylvania, Philadelphia
  • UPMC, Pittsburgh
Menerima pesertaFase 4
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT05034432

A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 2
Usia 8 ke atas · Pria · Diperbarui 4 Mei 2026 · NCT06092034

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  • Penn Presbyterian Medical Center, Philadelphia
  • Allegheny General Hospital, Pittsburgh
  • University of Pittsburgh Medical Center, Pittsburgh
Menerima pesertaFase 3
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 27 Mar 2026 · NCT06128629

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.